Teva gets FDA Approval for Generic Requip

GlaxoSmithKline’s (GSK) Requip is used to treat both Parkinson’s disease and severe cases of restless leg syndrome.

The drug comes off patent on 19 May 2008, and Israeli drug company Teva Pharmaceutical Industries Ltd. has received tentative approval from the FDA (Food and Drug Administration) for their generic version of  tablets.
U.S. sales of the drug are about $455 million a year.

This entry was posted on Monday, December 3rd, 2007 at 3:24 pm and is filed under Israel IP, Israel Related, News, Patents, Teva, drugs, pharmaceuticals, pharmaceuticals and Biotechnology. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.

Leave a Reply